CHRS — Coherus Biosciences Share Price
0.000.00%
Last trade - 00:00- $251.35m
- $608.05m
- $257.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.98 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.23% | ||
| Return on Equity | n/a | ||
| Operating Margin | -78.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 356.07 | 475.82 | 326.55 | 211.04 | 257.24 | 261.92 | 357.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +32.12 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
Directors
- Dennis Lanfear CHM (65)
- McDavid Stilwell CFO (50)
- Vladimir Vexler CSO (63)
- Thomas Fitzpatrick OTH
- Theresa LaVallee OTH (52)
- Mats Wahlstrom LED (66)
- Lee Newcomer DRC (69)
- Ali Satvat IND (43)
- Mark Stolper IND (49)
- Kimberly Tzoumakas IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 29th, 2010
- Public Since
- November 6th, 2014
- No. of Shareholders
- 85
- No. of Employees
- 306
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 112,714,488
- Address
- C/O DENNIS M. LANFEAR, REDWOOD CITY, 94065
- Web
- https://www.coherus.com/
- Phone
- +1 6506493530
- Auditors
- Ernst & Young LLP
Upcoming Events for CHRS
Coherus BioSciences Inc Annual Shareholders Meeting
Q2 2024 Coherus BioSciences Inc Earnings Release
Similar to CHRS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Coherus Biosciences share price?
As of Today at 19:05 UTC, shares in Coherus Biosciences are trading at $2.23. This share price information is delayed by 15 minutes.
How has the Coherus Biosciences share price performed this year?
Shares in Coherus Biosciences last closed at $2.23 and the price had moved by -72.57% over the past 365 days. In terms of relative price strength the Coherus Biosciences share price has underperformed the S&P500 Index by -77.85% over the past year.
What are the analyst and broker recommendations for Coherus Biosciences?
The overall consensus recommendation for Coherus Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Coherus Biosciences dividend yield?
Coherus Biosciences does not currently pay a dividend.
Does Coherus Biosciences pay a dividend?
Coherus Biosciences does not currently pay a dividend.
When does Coherus Biosciences next pay dividends?
Coherus Biosciences does not currently pay a dividend.
How do I buy Coherus Biosciences shares?
To buy shares in Coherus Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Coherus Biosciences?
As of the previous close price of $2.23, shares in Coherus Biosciences had a market capitalisation of $251.35m.
Where are Coherus Biosciences shares listed?
Here are the trading details for Coherus Biosciences:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CHRS
What kind of share is Coherus Biosciences?
Based on an overall assessment of its quality, value and momentum Coherus Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Coherus Biosciences share price forecast for 2024?
The analyst consensus target price for shares in Coherus Biosciences is $10.43. That is 367.71% above the last closing price of $2.23.
Analysts covering Coherus Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.58 for the next financial year.
What is the trend in the Coherus Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Coherus Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -50.04%.
As of the last closing price of $2.23, shares in Coherus Biosciences were trading -30.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Coherus Biosciences PE Ratio?
The Coherus Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Coherus Biosciences?
Coherus Biosciences' management team is headed by:
- Dennis Lanfear - CHM
- McDavid Stilwell - CFO
- Vladimir Vexler - CSO
- Thomas Fitzpatrick - OTH
- Theresa LaVallee - OTH
- Mats Wahlstrom - LED
- Lee Newcomer - DRC
- Ali Satvat - IND
- Mark Stolper - IND
- Kimberly Tzoumakas - IND